| Trial ID: | L2944 |
| Source ID: | NCT00482729
|
| Associated Drug: |
Sitagliptin Phosphate (+) Metformin Hydrochloride
|
| Title: |
MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00482729/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: sitagliptin phosphate (+) metformin hydrochloride|DRUG: metformin
|
| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 18, A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent., Baseline and Week 18 | Secondary: Number of Patients With A1C < 7.0% at Week 18, Week 18|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18, FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL., Baseline and Week 18 | Other: Change From Baseline in A1C at Week 44, A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent., Baseline and Week 44|Number of Patients With A1C < 7.0% at Week 44, Week 44
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
1246
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-06-19
|
| Completion Date: |
2009-04-27
|
| Results First Posted: |
2010-03-15
|
| Last Update Posted: |
2017-06-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00482729
|
